Atea Pharmaceuticals Achieves Favorable DDI Profile for BEM/RZR Fixed-Dose HCV Regimen in Phase 1

Phase 1 drug-drug interaction data for Atea Pharmaceuticals' fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) show no clinically meaningful interaction with omeprazole or rosuvastatin, removing a formulation complexity that has historically complicated multi-component antiviral regimens and their regulatory dossiers. The findings were presented at the EASL Congress 2026 in Barcelona on May 27.

For regulatory affairs leads preparing NDA or MAA submissions, the DDI data carry direct implications for labeling strategy. Because approximately 80 percent of HCV patients in the US are managing concurrent medications, a clean interaction profile reduces the contraindication burden in prescribing information and simplifies the risk management sections required under 21 CFR Part 201 and ICH M12 guidance on drug interaction studies. No dose-adjustment language appears warranted for co-administration with proton pump inhibitors or statins based on the Phase 1 results.

From a manufacturing and process validation standpoint, the fixed-dose combination format introduces its own complexity. Demonstrating physicochemical compatibility between bemnifosbuvir and ruzasvir within a single dosage unit requires robust comparability data across batches, and any future scale-up will need to satisfy ICH Q10 pharmaceutical quality system requirements alongside process validation expectations under 21 CFR Part 211. The DDI results, while clinically derived, indirectly support formulation stability arguments by confirming that the two actives do not produce interaction-driven metabolite profiles that would complicate impurity specifications.

Atea also presented preclinical data for AT-587, a potential first-in-class direct-acting antiviral targeting hepatitis E virus (HEV). High in vitro potency and in vivo efficacy were reported against HEV genotype 3 and 4, strains increasingly recognized as life-threatening in immunocompromised populations including solid organ transplant recipients and patients with hematologic malignancies. No approved antiviral therapy exists for HEV, and current off-label options carry tolerability limitations. A first-in-human study for AT-587 is planned for mid-2026.

The BEM/RZR program's near-term regulatory trajectory depends on topline Phase 3 data from the C-BEYOND and C-FORWARD trials, which will determine whether the DDI profile demonstrated in Phase 1 holds across the broader patient population and supports the submission package Atea will need to advance toward approval.

Source: Atea Pharmaceuticals, Inc. via GlobeNewswire, May 27, 2026.